Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on June 3, 2019, for the month of June 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing discloses the Company's issued share capital as of May 31, 2019:
- Total Issued Shares: 5,381,466,396 Ordinary Shares of 25 pence each.
- Treasury Shares: 393,505,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,987,960,446.
No material changes versus a prior comparable period are discussed in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to establish the denominator for shareholder interest calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,987,960,446) against the latest 20-F annual report to ensure consistency.
- Confirm the number of shares held in Treasury (393,505,950) to accurately calculate free float.
- Note that this filing does not contain operational or financial performance updates for the period.